Serotonin transporter gene influences the time course of improvement of "core" depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders.

摘要: Abstract The short variant of the serotonin transporter gene (SERTPR) has been consistently associated with a poorer response to treatment various selective reuptake inhibitors (SSRIs). Antidepressant is not unitary phenomenon, however, and we here hypothesized that SERTPR effect could be specific some types symptomatology. sample comprised 281 inpatients affected by mood disorders treated for major depression SSRIs. total depressive scores all patients were analyzed in previous reports, but symptomatologic clusters examined previously. 21-item Hamilton Rating Scale Depression (HAM-D) was administered evaluate symptoms at baseline weekly over 6 weeks treatment. All genotyped polymorphism. Compared l/l l/s polymorphisms, s/s showed slower improvement “core” somatic anxiety symptoms, they did differ from other regarding such as insomnia motor retardation. These findings support view SSRIs phenomenon as, least part, genetically driven. may concurrently participating activity anatomic brain regions differentially involved anxiety; further studies are required examine these complex interactions.